Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Renalytix Ai Plc LSE:RENX London Ordinary Share GB00BYWL4Y04 ORD 0.25P
  Price Change % Change Share Price Shares Traded Last Trade
  -25.00 -5.02% 473.00 9,461 08:15:25
Bid Price Offer Price High Price Low Price Open Price
466.00 480.00 490.00 473.00 490.00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology -10.61 -16.00 281
Last Trade Time Trade Type Trade Size Trade Price Currency
08:16:46 O 1,000 470.00 GBX

Renalytix Ai (RENX) Latest News

More Renalytix Ai News
Renalytix Ai Investors    Renalytix Ai Takeover Rumours

Renalytix Ai (RENX) Discussions and Chat

Renalytix Ai (RENX) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
08:16:47470.001,0004,700.00O
08:15:26480.00100480.00O
08:15:12467.704,00018,708.00O
08:12:17481.001,2005,772.00O
08:05:02481.00100481.00O
View all Renalytix Ai trades in real-time

Renalytix Ai (RENX) Top Chat Posts

DateSubject
27/11/2020
08:20
Renalytix Ai Daily Update: Renalytix Ai Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker RENX. The last closing price for Renalytix Ai was 498p.
Renalytix Ai Plc has a 4 week average price of 436p and a 12 week average price of 415p.
The 1 year high share price is 645p while the 1 year low share price is currently 173.50p.
There are currently 59,416,134 shares in issue and the average daily traded volume is 605,327 shares. The market capitalisation of Renalytix Ai Plc is £281,038,313.82.
26/11/2020
15:22
james188: az4hr - N+1 Singer issued a broker note on 27th October 2020 in which they stated that "Renalytix will be distributed c. 10% of all income from the [Kantaro] JV." Note that is not limited to antibody test sales. I do not know how they arrived at that figure. I do know that Kantaro issued 750 Class A units to Mount Sinai (in consideration of the grant of certain IP rights) and 250 Class A units to RENX (in consideration of advisory services for a 5 year period rendered to Kantaro by RENX). Assuming that all those units have exactly the same rights, that does not provide the answer. Both entities also made interest bearing loans to Kantaro, which I assume are not counted in the 10% figure. Interest is currently being rolled up. There are also other contracts that Kantaro entered into with Mount Sinai which entitle Mount Sinai to payments once certain targets are achieved. How all that drills down to the 10% net income figure stated by N+1 Singer would be a good question to ask RENX.
26/11/2020
11:04
bramcych: I agree it is crazy that they didn't issue a UK RNS. What is the uk share price equivalent of the US closing price of 13.80?
25/11/2020
15:21
74tom: At last!! RENX get a 10% royalty on any sales revenue, there were a lot of different prices quoted a few months back ranging from $40 up to $100+... either way, the timing is very good with the vaccine rollout about to start, and with Bio Techne able to manufacture 10m a month straight off there should be considerable benefit. If they sell 10m tests over the course of the next 6 months at $40 per test that would bring in $40m of profit for RENX. Huge numbers are possible here.
25/11/2020
14:48
nimbo1: its a bit of a shame this didn't happen 3 months ago - it probably would have doubled the share price in the US but things take time!
09/10/2020
07:47
74tom: The quiet period continues, but I believe we'll see the finals in the next 10 days (to align with the NASDAQ listing date of 17/07 & provide quarterly financials). By the way @Wan, I have been watching CareDX the last couple of weeks as they continue their ascent. Sadly I'm not a holder, but it bodes extremely well for the commerical path of RENX & Verici to see them go from strength to strength. They closed last night at $50.5 for a market cap of $2.5b, three years ago they had a share price around $3 and market cap of $100m or so. They are still loss making as well, so it just shows what can be achieved by executing & scaling revenues!
17/9/2020
09:12
welshborderer: Hi All, As a newbie forgive me if this has been posted elsewhere but note that while Halifax have credited the Dividend in Specie they will not allow it within an ISA. Anyone know if this can be challenged when circumstances change in the future? This is their take on the situation and have credited the shares at a value of 1p per share: RENALYTIX AI PLC - Important Information Dividend in Specie. 1 Additional New Verici Dx Limited (Verici) Ordinary share for each Existing Renalytix AI Plc (Renalytix) share held on 10th July 2020, being the Ex-entitlement date. On 7th July 2020, Renalytix announced its intention to distribute shares of its wholly-owned subsidiary Verici. We can confirm that the additional Verici shares have been credited to your account. Whilst the Verici shares are reflected on your account, under the terms of the distribution, the Verici shares are held in Trust on behalf of Shareholders for a period of up to 2 years, dependent on admission to trading on a recognised stock exchange. During this period, you will be unable to buy, sell or transfer the Verici shares. Please note that as the Verici shares are held in Trust they are not eligible to be held within a ShareBuilder account, therefore we have taken the necessary steps to transfer the shares to your ShareDealing Account. In accordance with our Terms & Conditions, no fractions of shares have been transferred. All fractional holdings have been rounded down to the nearest whole share. As Verici shares are not listed on a recognised Exchange, they do not qualify to be held within an ISA product under HMRC Guidelines. Therefore, if you held your New Verici shares in an ISA we have transferred these to your Share Dealing Account. If you did not have a Share Dealing Account, we have opened one for you. We will notify you on receipt of any further information should an application be made to list the Verici shares on a Stock Exchange. Please be aware, however, that there can be no guarantee that any such application will materialise. Should you wish to find more information about the Dividend in Specie, please visit the Renalytix website, hxxps://renalytixai.com/investors/
06/8/2020
08:01
74tom: The nice thing here is that a higher RENX share price is beneficial to Mount Sinai as it increases the value of their 15% stake. A larger portion of Kantaro may also reduce RENX's need for future equity funding, so there are a few reasons why this might happen. It's a fascinating & pretty unique situation that is unfolding.
21/7/2020
14:20
nimbo1: There will be plenty of pi's selling because it didn't double day one. They need to execute from an operational perspective - as and when they do share price will increase dramatically I would have thought. We are now tied to the nasdaq price and other than the insti's who purchased shares over there no other investors have heard of renx yet. Im sure when Stifel resume coverage and put out an investment note / renx release their first news on nasdaq you'll see interest pick up. also the share price has travelled quite a long way relatively quickly - you always get periods of distribution after such times...especially after raising money! The key thing is they have their money so the potential to be a great success is now in their hands : )
09/7/2020
11:38
74tom: Re. Distribution of shares in Verici, it seems logical to grant shares in the new entity on a 1-1 basis. The book value of Verici is $2m, so they’ve minimised the ex dividend in specie impact on the RENX share price (it’ll be about 2.7p), IMO better to do it this way than the way EKF split off RENX, which resulted in a 30% ex div in specie markdown. My opinion is that they’ll look to raise around £20m when they IPO, and the pre cash valuation will likely be similar to the RENX IPO (£45m). They simply wouldn’t bother with the spin off process to list for much less than this. However, even a much lower pre IPO valuation of £20-25m would still result in a very nice paper profit vs the current book valuation... So based on the above assumptions, I’m happy with the 1 year lock in - it’s worth it to be get in at the very bottom. What are your thoughts?
07/7/2020
14:48
74tom: The exciting thing about RENX is the combination of huge addressable target market, the presence of a significant and growing IP moat & the macro tailwinds driving market appetite for health-tech companies (especially those listed in the US). For these reasons alone the escalator can go an awful lot higher over the coming years. Stifel have forecast revenues of $390m in 5 years time. Comparators such as Guardant Health reported $67m revenue last quarter & are valued at over $8b. So evidently IF RENX can achieve their growth ambitions then the share price will take care of itself. @Nimbo I note Livongo smashed their Q2 target by around 20% ($86m revenue), the full year forecast was $300m (likely to be upgraded by a decent amount!), and they’re now valued at $9b so 30x revenue. The critical next step for RENX is recording first revenues via Mount Sinai, hopefully in the very near future...
Renalytix Ai share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
LSE
RENX
Renalytix ..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20201127 08:31:50